secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scinai Immunotherapeutics Ltd. (SCNI)
CIK:        0001611747
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001213900-23-047493
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG
--------------------------------------------------------------------------------

- Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
- Within 45 days of June 4, 2023, BiondVax will issue 17,000 American Depositary Shares to licensors, with a 1-year lock-up.
- Milestone payments due upon IND submission and clinical study initiations; royalties on net sales apply.
- BiondVax must submit an IND by June 30, 2025, or face termination by December 31, 2026, unless extended via EUR 500,000 payments.
- Plans to initiate a preclinical in vivo efficacy study in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/0001213900-23-047493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1611747/000121390023047493/ea180017-8k_biondvax.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-047493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer